Tagged with Opinion,

USA Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond.   To keep pace with the remarkable and continuing growth of gene therapy, FDA’s…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

USA AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward.   Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on…

USA Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to combat this threat.   Keeping patient data safe and secure remains a challenge. Thanks to a 9-year review of experiences in the United States, we know…

Opinion Within the pharmaceutical space, Eurasia Group’s Aditya Bhattacharji expects politics to drive significant changes in regulatory and legal affairs. He explains how the evolving dynamics can be characterized by two themes.   Regulatory Right-Sizing The status quo is highly unlikely to hold in the regulatory space. The growing and largely…

Opinion Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a prediction for the industry’s future, including a significantly increased amount of interplay between large technology and pharma companies.   The past two decades have seen an explosion of biomedical…

Opinion Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in 2018, the highly promising landscape for further approvals.   The landscape for approved CBD products is highly promising and will undoubtedly lead to additional FDA…

Opinion The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug prices and reducing abandonment rates.   Generic and biosimilar prescription drugs manufactured by member companies of the Association for Accessible Medicines (AAM) play an integral role in the…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities involving companies with artificial intelligence/machine learning platforms and technologies and their application to healthcare companies.   Artificial Intelligence Advances in technologies, an incorporation of entrants from outside the industry and changing consumer…

Opinion Dr Valters Bolevics, CEO of the Association of International Research-based Pharmaceutical Manufacturers (SIFFA) in Latvia, gives an overview of recent market changes affecting the Latvian pharmaceutical market, regulatory upgrades, and growth projections for 2020.   Following a breakthrough year in 2018, 2019 has also seen numerous positive changes for the…

Opinion Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements – infrastructure, regulations, and the availability of Asia-specific data – to ensure AI can be effectively utilised to improve patient outcomes in the region.   Healthcare, manufacturing,…

Opinion Eurasia Group’s Aditya Bhattacharji and Sarah Hassan identify and unpack the top three political and policy issues that multinational pharmaceutical firms are currently focusing on.   Issue One: The Global Economy Over the past month, one theme stood out at both the central bankers’ confab in Jackson Hole, Wyoming and…